Taiwan FDA approved a record breaking 170 new drugs in 2015

22 February 2016

In order to increase the nation’s access to new drugs, the Taiwan Food and Drug Administration (TFDA) has sped up the review procedure for new drugs. According to the TFDA, 170 new drugs were approved last year, up by 30%. This was a record breaking achievement.

Among the approved new drugs, 13% are cancer drugs. They also included two new drugs which were developed and had their world debut in Taiwan, bringing benefits to Taiwanese patients with hyperphosphatemia and metastatic pancreatic cancer, according to a posting on the web site of the local pharma association, the IRPMA.

According to the TFDA’s data, 27 cases out of the total 170 approved cases are new drugs developed in Taiwan, and 143 are imported drugs. The number of successful applications filed by local developers has been on a rise five years in a row.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK